vTv Therapeutics Launches Phase 2 Trial for Diabetes Drug Cadisegliatin in the Middle East

vTv Therapeutics has submitted a Phase 2 clinical study protocol for cadisegliatin to the Department of Health Abu Dhabi. The trial will test the drug as an oral add-on therapy for people with type 2 diabetes who use insulin.

The study marks a new step in the company's efforts to expand cadisegliatin's reach beyond the US, where it is being explored for type 1 diabetes.

The 12-month trial will be double-blind, randomised, and placebo-controlled. Around 300 patients across the UAE, Jordan, and Tunisia will take part. Participants will receive either a 400 mg or 800 mg daily dose of cadisegliatin—or a placebo.

The first patient visit is expected in early 2026. vTv Therapeutics is working with IROS, a UAE-based clinical research organisation, to run the study. IROS specialises in clinical trials and real-world data collection.

Cadisegliatin is an oral, liver-selective glucokinase activator. It could become the first drug of its kind as an add-on to insulin. The study aims to check its safety and effectiveness over a full year.

By February 2026, vTv plans to pick 3-5 more countries for future trials. Selection will depend on diabetes rates, strong regulatory systems, experienced research sites, and cost efficiency. Possible regions include parts of Europe and Asia-Pacific.

The trial will provide longer-term data on cadisegliatin in type 2 diabetes patients. Results may support its use alongside insulin in more regions. The study also strengthens vTv's collaboration with IROS in expanding clinical research beyond the US.